- (194-21) Effect of ziltivekimab in patients with ASCVD and CKD (Phase 3 clinical trial, appropriate for patients with atherosclerotic cardiovascular disease and chronic kidney disease)
- (267-21) Use of the Guardian™ Connect system with Smart Connected Devices (Appropriate for patients with type 1 or type 2 diabetes)
- (255-20) A Post Approval Study to Evaluate the Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System Used Nonadjunctively (Post approval study, appropriate for patients with type 1 or type 2 diabetes)
- (262-22) A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes (2IQP)
Your participation in any trial is entirely voluntary. You may decide to withdraw at any time without losing the benefits of your standard medical care.